Updated:
Shanghai Ruiyan Investment Management
Shanghai Ruiyan Investment Management Co., Ltd. focuses on investing in and incubating frontier translation and technology innovation enterprises.
Shanghai Ruiyan Investment Management
Shanghai Ruiyan Investment Management Co., Ltd. focuses on investing in and incubating frontier translation and technology innovation enterprises. The firm aims to build a “proof-of-concept + fund + incubator” model leveraging the Zhangjiang biopharma industry cluster, helping life-science startup teams through early-stage challenges. Its mission is to improve quality of life and advance the healthcare industry by investing in and supporting innovative biopharmaceutical concepts.
General information
Firm type
Venture Capital
Year founded
2014
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Principals
曲奕 Yi QU，管理合伙人
秦玮 WEI QIN，人力资本负责人
刘万富 WANFU LIU，首席资本市场顾问
Sector focus
Frequently asked questions
Which sectors does Shanghai Ruiyan Investment Management prioritize?
Ruiyan concentrates on biopharmaceutical innovation across four thematic buckets: new molecular entities (small-molecule compounds requiring structural optimization), new therapeutic technologies (gene editing, immunotherapy, stem-cell approaches), new delivery technologies (lipid nanoparticles, polymer-based carriers, viral vectors), and cross-disciplinary applications that merge biopharma with AI, nanotechnology, or tissue engineering.
How does Shanghai Ruiyan Investment Management source its deal flow?
Available evidence points to a sourcing model embedded in Shanghai's public-sector incubation ecosystem. Ruiyan partners with Shenze Incubator, a state-linked life-science accelerator, and operates the IN³ LAB platform, which hosts industry forums and co-invests alongside scientist-founders commercializing research from Chinese universities and government laboratories.
Does Shanghai Ruiyan Investment Management invest outside China?
All currently visible activity — website, portfolio references, incubator partnerships — is anchored in mainland China, specifically Shanghai and the Yangtze River Delta. No disclosed cross-border investments or non-China portfolio companies have been identified in public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: